Lohasz Christian, Loretan Jacqueline, Sterker Dario, Görlach Ekkehard, Renggli Kasper, Argast Paul, Frey Olivier, Wiesmann Marion, Wartmann Markus, Rausch Martin, Hierlemann Andreas
ETH Zürich, Department of Biosystems Science and Engineering, Basel, Switzerland.
Novartis Institutes for Biomedical Research, Basel, Switzerland.
Front Pharmacol. 2021 Dec 21;12:785851. doi: 10.3389/fphar.2021.785851. eCollection 2021.
Understanding the pharmacokinetic/pharmacodynamic (PK/PD)-relationship of a drug candidate is key to determine effective, yet safe treatment regimens for patients. However, current testing strategies are inefficient in characterizing responses to fluctuating drug concentrations during multi-day treatment cycles. Methods based on animal models are resource-intensive and require time, while traditional cell-culturing methods usually do not provide temporally-resolved information on the effects of -like drug exposure scenarios. To address this issue, we developed a microfluidic system to 1) culture arrays of three-dimensional spheroids to 2) apply specific dynamic drug exposure profiles, and to 3) analyze spheroid growth and the invoked drug effects in 3D by means of 2-photon microscopy at tissue and single-cell level. Spheroids of fluorescently-labeled T-47D breast cancer cells were monitored under perfusion-culture conditions at short time intervals over three days and exposed to either three 24 h-PK-cycles or a dose-matched constant concentration of the phosphatidylinositol 3-kinase inhibitor BYL719. While the overall efficacy of the two treatment regimens was similar, spheroids exposed to the PK profile displayed cycle-dependent oscillations between regression and regrowth. Spheroids treated with a constant BYL719 concentration regressed at a steady, albeit slower rate. At a single-cell level, the cell density in BYL719-treated spheroids oscillated in a concentration-dependent manner. Our system represents a versatile tool for in-depth preclinical characterization of PK/PD parameters, as it enables an evaluation of drug efficacy and/or toxicity under realistic exposure conditions.
了解候选药物的药代动力学/药效学(PK/PD)关系是确定对患者有效且安全的治疗方案的关键。然而,当前的测试策略在表征多日治疗周期中对波动药物浓度的反应方面效率低下。基于动物模型的方法资源密集且耗时,而传统的细胞培养方法通常无法提供类似药物暴露情况下效应的时间分辨信息。为了解决这个问题,我们开发了一种微流控系统,用于1)培养三维球体阵列,2)应用特定的动态药物暴露曲线,以及3)通过双光子显微镜在组织和单细胞水平分析球体生长和引发的药物效应。在灌注培养条件下,以短时间间隔对荧光标记的T-47D乳腺癌细胞球体进行了三天的监测,并使其暴露于三个24小时的PK周期或磷脂酰肌醇3激酶抑制剂BYL719的剂量匹配恒定浓度下。虽然两种治疗方案的总体疗效相似,但暴露于PK曲线的球体在消退和再生长之间表现出周期依赖性振荡。用恒定浓度的BYL719处理的球体以稳定但较慢的速度消退。在单细胞水平上,BYL719处理的球体中的细胞密度以浓度依赖性方式振荡。我们的系统代表了一种用于深入临床前表征PK/PD参数的通用工具,因为它能够在实际暴露条件下评估药物疗效和/或毒性。